Antismoking agents do not contribute synergistically to semaglutide’s ability to reduce alcohol intake in rats
Open accessThe DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
Preclinical studies have identified glucagon-like peptide-1 receptor (GLP-1R) agonists, and the antismoking agents varenicline and bupropion as tentative agents for treatment of alcohol use disorder (AUD). Combining different medications is a recent approach that has gained attention regarding heterogenous and difficult-to-treat diseases, like AUD. Successfully, this approach has been tested for the combination of varenicline and bupropion as it prevents relapse to alcohol drinking in rats. However, studies assessing the effects of the combination of semaglutide, an FDA-approved GLP-1R agonist for diabetes type II, and varenicline or bupropion to reduce alcohol intake in male and female rats remains to be conducted. Another approach to influence treatment outcome is to combine a medication with feeding interventions like high fat diet (HFD). While HFD reduces alcohol intake, the ability of the combination of HFD and semaglutide to alter alcohol drinking is unknown and thus the subject for a pilot study. Therefore, three intermittent alcohol drinking experiments were conducted to elucidate the effectiveness of these treatment combinations. We show that semaglutide, bupropion or HFD reduces alcohol intake in male as well as female rats. While various studies reveal beneficial effects of combinatorial pharmacotherapies for the treatment of AUD, we herein do not report any additive effects on alcohol intake by adding either varenicline or bupropion to semaglutide treatment. Neither does HFD exposure alter the ability of semaglutide to reduce alcohol intake. Although no additive effects by the combinatorial treatments are found, these findings collectively provide insight into possible monotherapeutical treatments for AUD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![FIGURE 1 Effects of the combination of semaglutide and varenicline on alcohol intake in male and female rats (A) Timeline for the alcohol drinking experiment in which male (n = 24) and female (n = 23) rats were injected with semaglutide, varenicline or their combination in a Latin square design. Red symbols alcohol drinking session [corresponding to alcohol drinking session shown in (B–M)], and blue a water drinking day. The syringe indicates the sessions in which a drug was injected. The timeline was created with BioRender.com. Males: compared to vehicle semaglutide alone or in combination with varenicline decreases (B) alcohol intake and (C) alcohol preference, but the combination does not decline these alcohol parameters more than semaglutide alone. On other hand, neither treatment altered the (D) water and (E) total fluid intake. Further, semaglutide as monotherapy or combined with varenicline reduces (F) food intake and (G) body weight change, but with a similar magnitude. Varenicline does not affect any of the studied parameters, and in comparison to varenicline the combination reduces alcohol intake, preference for alcohol, food intake and body weight change (Figures 1B–G). Females: in comparison to vehicle, semaglutide and the combination decreases (H) alcohol intake and (I) preference for alcohol, and no additive-like effects were found. Whereas the (J) water intake is unaltered by semaglutide or varenicline treatment, their combination increases water intake. On the contrary, (K) treatment does not affect the total fluid intake. Further, with a similar magnitude both semaglutide alone or in combination reduces (L) food intake and (M) body weight change. Varenicline does not affect any of the studied parameters, and in comparison to varenicline the combination reduces alcohol intake, preference for alcohol, food intake and body weight change and increases water intake (Figures 1H–M). Data are presented as mean ± SEM, significant data are illustrated by *p < 0.05, **p < 0.01, ***p < 0.001 in comparison to vehicle. +p < 0.05, ++p < 0.01, +++p < 0.001 in comparison to varenicline. Vehicle (Veh), semaglutide (Sem), varenicline (Var), semaglutide and varenicline combination (Com).](https://figures.cochat.ai/paper-figures/3fbc67a31e484d77b0410fa4d12202c1/antismoking-agents-do-not-contribute-synergistically-to-semaglutides-ability-to-figure-1.jpg)
![FIGURE 2 Effects of the combination of semaglutide and bupropion on alcohol intake in male and female rats (A) Timeline for the alcohol drinking experiment in which male (n = 8) and female (n = 8) rats were injected with semaglutide, bupropion or their combination in a Latin square design (three injections for each treatment). Red symbols alcohol drinking session [corresponding to alcohol drinking sessions 1–3 in (B–M)], and blue a water drinking day. The syringe indicates the sessions in which a drug was injected. The timeline was created with BioRender.com. Males: Compared to vehicle, semaglutide alone or in combination with bupropion decreases (B) alcohol intake and (C) preference for alcohol, and the decline is similar between these groups. Compared to bupropion monotherapy, the combination treatment lowers alcohol intake, but not preference. Moreover, in comparison to vehicle bupropion reduces alcohol intake without altering preference for alcohol. Although semaglutide (D) increases water intake, (E) the total fluid intake was unaltered by treatment. (F) Compared to vehicle, semaglutide alone or in combination with bupropion decreases food intake, and the decline is similar between these groups. In comparison to vehicle, bupropion reduces food intake. Compared to the bupropion monotherapy, the combination treatment lowers food intake further. (G) When it comes to the body weight, bupropion increases this parameter whereas its unaltered by semaglutide. The body weight is lower in rats treated with the combination therapy compared to either monotherapy. Females: Semaglutide, alone or in combination, reduces (H) alcohol intake and (I) preference for alcohol compared to vehicle, and this decrease is similar between the semaglutide and combination groups. Bupropion does not influence these alcohol parameters in females. The alcohol intake and preference are lower in female rats treated with the combination compared to those treated with bupropion. Whereas both semaglutide and the combination increase (J) water intake, only (K) semaglutide enhances the total fluid intake. (L) While semaglutide, bupropion and the combination reduce food intake with a similar magnitude, the combination treatment decreases it further compared to bupropion. (M) There are no treatment effects on body weight. Data are presented as mean ± SEM, significant data are illustrated by ***p < 0.001. Vehicle (Veh), semaglutide (Sem), bupropion (Bup), semaglutide and bupropion combination (Com).](https://figures.cochat.ai/paper-figures/e6ba92c7d271402eb59d7ac1412706d9/antismoking-agents-do-not-contribute-synergistically-to-semaglutides-ability-to-figure-2.jpg)
![FIGURE 3 Effects of high fat diet and its combination with semaglutide on alcohol drinking in male and female rats (A) Timeline for the alcohol drinking experiment in which male (n = 20) and female (n = 20) rats were exposed to high fat diet for 3 weeks. After 2 weeks of washout from HFD, rats were injected with semaglutide or vehicle, and exposed to HFD or regular chow. Red symbols alcohol drinking session [corresponding to alcohol drinking sessions 1–3 in (B–M)], and blue a water drinking day. The syringe indicates the sessions in which a drug was injected and HFD indicates when this was exposed. The timeline was created with BioRender.com. Males: (B) The alcohol intake is reduced by semaglutide (Sem), high fat diet (HFD) or their combination (Com), and the semaglutide response is unaltered by HFD. (C) Compared to vehicle (Veh), both semaglutide and the combination decrease the preference for alcohol. This decrease was similar in both these groups. (D) While the combination treatment increase water intake, (E) the total fluid intake is not affected by treatments. Semaglutide as well as the combination treatment decreases (F) food intake and (G) the body weight change. Moreover, HFD tends to decrease food intake and also tends to additively lower the ability of semaglutide to reduce food intake. Females: (H) both semaglutide treatment alone and its combination with HFD reduce alcohol drinking. Moreover, HFD decreases alcohol intake, while it does not alter the ability of semaglutide to lower alcohol intake. neither treatment affects (I) preference for alcohol, (J) water intake or (K) total fluid intake. (L) HFD, semaglutide or their combination reduces food intake, and HFD further reduces the ability of semaglutide to reduce food intake. (M) The body weight change is reduced after treatment with either semaglutide or the combination. HFD blunts the ability of semaglutide to reduce body weight change. Data are presented as mean ± SEM, significant data are illustrated by, *p < 0.05, **p < 0.01, ***p < 0.001 when compared to vehicle. +p < 0.05 illustrates significant effect when comparing the combination treatment to HFD.](https://figures.cochat.ai/paper-figures/aa0c64a62c3e4c06ab330e8f329bcd24/antismoking-agents-do-not-contribute-synergistically-to-semaglutides-ability-to-figure-3.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Animal models support that GLP-1RA treatment causally reduces alcohol intake, and GLP-1RAs may dampen the release of dopamine in the nucleus accumbens in response to alcohol intake as well as increase the breakdown of dopamine [17,84,85,86].”
From What Is Food Noise? A Conceptual Model of Food Cue Reactivity (2023) · cites this paper as [85]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 3×
“A finding previously shown in preclinical and clinical studies of obesity (Gabery et al., 2020; Wilding et al., 2021; Martins et al., 2022).”
BackgroundResultRehm, J., Mathers, C., Popova, S., Thavorncharoensap, M., Teerawattananon, Y., & Patra, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60746-7 · Cited by 3,870 · cited 1×
“The socioeconomic and medical severity of alcohol use disorder (AUD) is substantial (Rehm et al., 2009), and the limited efficacy of available treatments is thus a major concern (Heilig and Egli, 2006).”
BackgroundGLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647 · cited 1×
“GLP-1R agonists are hence approved as treatment of diabetes type II (Nauck et al., 2021).”
BackgroundO'Neil, P. M., Birkenfeld, A. L., McGowan, B., Mosenzon, O., Pedersen, S. D., Wharton, S., Carson, C. G., Jepsen, C. H., Kabisch, M., & Wilding, J. P. H. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31773-2 · Cited by 814 · cited 1×
“In accordance with previous studies in obese/diabetic man or rodents (Martins et al., 2022; O’Neil et al., 2018; Wilding et al., 2021; Gabery et al., 2020), semaglutide decreases food intake in the alcohol exposed male and female rats.”
ResultSemaglutide lowers body weight in rodents via distributed neural pathways.
Gabery, S., Salinas, C. G., Paulsen, S. J., Ahnfelt-Rønne, J., Alanentalo, T., Baquero, A. F., Buckley, S. T., Farkas, E., Fekete, C., Frederiksen, K. S., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.133429 · Cited by 717 · cited 3×
“A finding previously shown in preclinical and clinical studies of obesity (Gabery et al., 2020; Wilding et al., 2021; Martins et al., 2022).”
BackgroundResultREVIEW: Behavioural assessment of drug reinforcement and addictive features in rodents: an overview
Sanchis‐Segura, C., & Spanagel, R. (2006) · Addiction Biology · doi:10.1111/j.1369-1600.2006.00012.x · Cited by 629 · cited 1×
“They are in further accordance with studies on other GLP-1R agonists, where their systemic administration lowers alcohol intake (Sanchis-Segura and Spanagel, 2006; Davis et al., 2012; Egecioglu et al., 2013; Shirazi et al., 2013; Suchankova et al., 2015; Vallof et al., 2015; Thomsen et al., 2017; Thomsen et al., 2019;…”
ResultIntermittent Access to 20% Ethanol Induces High Ethanol Consumption in Long–Evans and Wistar Rats
Simms, J. A., Steensland, P., Medina, B., Abernathy, K. E., Chandler, L. J., Wise, R., & Bartlett, S. E. (2008) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2008.00753.x · Cited by 610 · cited 1×
“Male and female Rcc/Han Wistar rats (post-pubertal; Envigo, Horst, Netherland) known to display a high alcohol intake (Simms et al., 2008) were used.”
MethodGLP-1 physiology informs the pharmacotherapy of obesity
Drucker, D. J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101351 · Cited by 510 · cited 1×
“These findings provide additional support for combining GLP-1R agonists with other pharmacotherapies for the treatment of obesity (Drucker, 2022).”
BackgroundPharmacological treatment of alcohol dependence: Target symptoms and target mechanisms
HEILIG, M., & EGLI, M. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.02.001 · Cited by 377 · cited 1×
“, 2009), and the limited efficacy of available treatments is thus a major concern (Heilig and Egli, 2006).”
BackgroundSteensland, P., Simms, J. A., Holgate, J., Richards, J. K., & Bartlett, S. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705368104 · Cited by 365 · cited 2×
“While previous studies in male rats report that varenicline decreases alcohol drinking (Steensland et al., 2007; Ericson et al., 2009; Hendrickson et al., 2010; Feduccia et al., 2014; Froehlich et al., 2017), this was not confirmed in the present study of male and female rats using a similar dose of varenicline.”
BackgroundResultTreatment of Tobacco Smoking: A Review
Rigotti, N. A., Kruse, G. R., Livingstone-Banks, J., & Hartmann-Boyce, J. (2022) · JAMA · doi:10.1001/jama.2022.0395 · Cited by 361 · cited 1×
“Another treatment for smoking is the noradrenaline and dopamine reuptake inhibitor and nAChR antagonist, bupropion (for review see (Gadde and Xiong, 2007; Rigotti et al., 2022).”
BackgroundVarenicline Reduces Alcohol Self-Administration in Heavy-Drinking Smokers
McKee, S. A., Harrison, E. L. R., O'Malley, S. S., Krishnan-Sarin, S., Shi, J., Tetrault, J. M., Picciotto, M. R., Petrakis, I. L., Estevez, N., & Balchunas, E. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.01.029 · Cited by 298
Litten, R. Z., Ryan, M. L., Fertig, J. B., Falk, D. E., Johnson, B., Dunn, K. E., Green, A. I., Pettinati, H. M., Ciraulo, D. A., Sarid-Segal, O., et al. (2013) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e31829623f4 · Cited by 287 · cited 2×
“Moreover, as human studies reveal effects of varenicline in smokers with AUD (McKee et al., Mitchell et al., 2012; Litten et al., 2013; Roberts et al., 2017b; Roberts et al., 2017a; Falk et al., 2015; de Bejczy et al., 2015; Verplaetse et al., 2016), the possibility that varenicline reduces alcohol drinking in nicotin…”
BackgroundKlausen, M. K., Jensen, M. E., Møller, M., Le Dous, N., Jensen, A.-M. Ø., Zeeman, V. A., Johannsen, C.-F., Lee, A., Thomsen, G. K., Macoveanu, J., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.159863 · Cited by 262 · cited 15×
“Moreover, as human studies reveal effects of varenicline in smokers with AUD (McKee et al., Mitchell et al., 2012; Litten et al., 2013; Roberts et al., 2017b; Roberts et al., 2017a; Falk et al., 2015; de Bejczy et al., 2015; Verplaetse et al., 2016), the possibility that varenicline reduces alcohol drinking in nicotin…”
BackgroundInfluentialChuong, V., Farokhnia, M., Khom, S., Pince, C. L., Elvig, S. K., Vlkolinsky, R., Marchette, R. C. N., Koob, G. F., Roberto, M., Vendruscolo, L. F., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.170671 · Cited by 214 · cited 2×
“They further support the recent studies revealing that acute and repeated semaglutide treatment, at similar doses, reduces alcohol intake, relapse drinking and binge drinking in male and female rodents (Aranäs et al., 2023; Chuong et al., 2023).”
BackgroundResultThe glucagon-like peptide 1 analogue Exendin-4 attenuates alcohol mediated behaviors in rodents
Egecioglu, E., Steensland, P., Fredriksson, I., Feltmann, K., Engel, J. A., & Jerlhag, E. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2012.11.009 · Cited by 207 · cited 1×
“They are in further accordance with studies on other GLP-1R agonists, where their systemic administration lowers alcohol intake (Sanchis-Segura and Spanagel, 2006; Davis et al., 2012; Egecioglu et al., 2013; Shirazi et al., 2013; Suchankova et al., 2015; Vallof et al., 2015; Thomsen et al., 2017; Thomsen et al., 2019;…”
ResultSelf-citationGut Peptide GLP-1 and Its Analogue, Exendin-4, Decrease Alcohol Intake and Reward
Shirazi, R. H., Dickson, S. L., & Skibicka, K. P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061965 · Cited by 187 · cited 2×
“Among areas of interest is those central for reward such as nucleus accumbens, ventral tegmental area and laterodorsal tegmental area as they participate in the interaction between alcohol and GLP-1 (Shirazi et al., 2013; Abtahi et al., 2018; Vallöf et al., 2019; Colvin et al., 2020; Dixon et al., 2020).”
BackgroundResultVarenicline decreases alcohol consumption in heavy-drinking smokers
Mitchell, J. M., Teague, C. H., Kayser, A. S., Bartlett, S. E., & Fields, H. L. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2717-x · Cited by 179 · cited 14×
“Moreover, as human studies reveal effects of varenicline in smokers with AUD (McKee et al., Mitchell et al., 2012; Litten et al., 2013; Roberts et al., 2017b; Roberts et al., 2017a; Falk et al., 2015; de Bejczy et al., 2015; Verplaetse et al., 2016), the possibility that varenicline reduces alcohol drinking in nicotin…”
BackgroundInfluentialSemaglutide reduces alcohol intake and relapse-like drinking in male and female rats
Aranäs, C., Edvardsson, C. E., Shevchouk, O. T., Zhang, Q., Witley, S., Blid Sköldheden, S., Zentveld, L., Vallöf, D., Tufvesson-Alm, M., & Jerlhag, E. (2023) · eBioMedicine · doi:10.1016/j.ebiom.2023.104642 · Cited by 158 · cited 3×
“Additionally, semaglutide is detected in nucleus accumbens after its systemic injection in alcohol drinking male and female rats (Aranäs et al., 2023).”
BackgroundResultSelf-citationVallöf, D., Maccioni, P., Colombo, G., Mandrapa, M., Jörnulf, J. W., Egecioglu, E., Engel, J. A., & Jerlhag, E. (2016) · Addiction Biology · doi:10.1111/adb.12295 · Cited by 150 · cited 1×
“They are in further accordance with studies on other GLP-1R agonists, where their systemic administration lowers alcohol intake (Sanchis-Segura and Spanagel, 2006; Davis et al., 2012; Egecioglu et al., 2013; Shirazi et al., 2013; Suchankova et al., 2015; Vallof et al., 2015; Thomsen et al., 2017; Thomsen et al., 2019;…”
ResultSelf-citationSuchankova, P., Yan, J., Schwandt, M. L., Stangl, B. L., Caparelli, E. C., Momenan, R., Jerlhag, E., Engel, J. A., Hodgkinson, C. A., Egli, M., et al. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.68 · Cited by 146 · cited 16×
“Moreover, as human studies reveal effects of varenicline in smokers with AUD (McKee et al., Mitchell et al., 2012; Litten et al., 2013; Roberts et al., 2017b; Roberts et al., 2017a; Falk et al., 2015; de Bejczy et al., 2015; Verplaetse et al., 2016), the possibility that varenicline reduces alcohol drinking in nicotin…”
BackgroundResultInfluentialSelf-citationEricson, M., Löf, E., Stomberg, R., & Söderpalm, B. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.147058 · Cited by 116 · cited 2×
“While previous studies in male rats report that varenicline decreases alcohol drinking (Steensland et al., 2007; Ericson et al., 2009; Hendrickson et al., 2010; Feduccia et al., 2014; Froehlich et al., 2017), this was not confirmed in the present study of male and female rats using a similar dose of varenicline.”
BackgroundResultVarenicline for Treatment of Alcohol Dependence: A Randomized, Placebo‐Controlled Trial
de Bejczy, A., Löf, E., Walther, L., Guterstam, J., Hammarberg, A., Asanovska, G., Franck, J., Isaksson, A., & Söderpalm, B. (2015) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.12854 · Cited by 105
Chatterjee, S., & Bartlett, S. E. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710790966597 · Cited by 103 · cited 1×
“Novel treatments are therefore needed, and among those that has been identified through preclinical studies are glucagon-like peptide-1 receptor (GLP-1R) agonists, and the antismoking agents varenicline and bupropion (for review see (Chatterjee and Bartlett, 2010; Soderpalm et al., 2020; Tufvesson-Alm et al., 2022).”
BackgroundMarty, V. N., Farokhnia, M., Munier, J. J., Mulpuri, Y., Leggio, L., & Spigelman, I. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.599646 · Cited by 102 · cited 3×
“Semaglutide is the most recent clinically available GLP-1R agonist shown to reduce alcohol drinking in rodents (Marty et al., 2020; Aranäs et al., 2023; Chuong et al., 2023).”
BackgroundResultHendrickson, L. M., Zhao-Shea, R., Pang, X., Gardner, P. D., & Tapper, A. R. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.2601-10.2010 · Cited by 99 · cited 2×
“While previous studies in male rats report that varenicline decreases alcohol drinking (Steensland et al., 2007; Ericson et al., 2009; Hendrickson et al., 2010; Feduccia et al., 2014; Froehlich et al., 2017), this was not confirmed in the present study of male and female rats using a similar dose of varenicline.”
BackgroundResultThomsen, M., Dencker, D., Wörtwein, G., Weikop, P., Egecioglu, E., Jerlhag, E., Fink‐Jensen, A., & Molander, A. (2017) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2017.07.014 · Cited by 99 · cited 1×
“They are in further accordance with studies on other GLP-1R agonists, where their systemic administration lowers alcohol intake (Sanchis-Segura and Spanagel, 2006; Davis et al., 2012; Egecioglu et al., 2013; Shirazi et al., 2013; Suchankova et al., 2015; Vallof et al., 2015; Thomsen et al., 2017; Thomsen et al., 2019;…”
ResultSelf-citationEffects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys
Thomsen, M., Holst, J. J., Molander, A., Linnet, K., Ptito, M., & Fink-Jensen, A. (2019) · Psychopharmacology · doi:10.1007/s00213-018-5089-z · Cited by 93
Vallöf, D., Kalafateli, A. L., & Jerlhag, E. (2019) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2019.02.006 · Cited by 84 · cited 1×
“Among areas of interest is those central for reward such as nucleus accumbens, ventral tegmental area and laterodorsal tegmental area as they participate in the interaction between alcohol and GLP-1 (Shirazi et al., 2013; Abtahi et al., 2018; Vallöf et al., 2019; Colvin et al., 2020; Dixon et al., 2020).”
BackgroundSelf-citationGastric bypass surgery attenuates ethanol consumption in ethanol-preferring rats
Davis, J. F., Schurdak, J. D., Magrisso, I. J., Mul, J. D., Grayson, B. E., Pfluger, P. T., Tschöp, M. H., Seeley, R. J., & Benoit, S. C. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.01.035 · Cited by 81 · cited 1×
“They are in further accordance with studies on other GLP-1R agonists, where their systemic administration lowers alcohol intake (Sanchis-Segura and Spanagel, 2006; Davis et al., 2012; Egecioglu et al., 2013; Shirazi et al., 2013; Suchankova et al., 2015; Vallof et al., 2015; Thomsen et al., 2017; Thomsen et al., 2019;…”
ResultWilliams, D. L., Hyvarinen, N., Lilly, N., Kay, K., Dossat, A., Parise, E., & Torregrossa, A.-M. (2011) · Physiology & Behavior · doi:10.1016/j.physbeh.2011.04.005 · Cited by 78
Sirohi, S., Schurdak, J. D., Seeley, R. J., Benoit, S. C., & Davis, J. F. (2016) · Physiology & Behavior · doi:10.1016/j.physbeh.2016.04.013 · Cited by 76 · cited 1×
“As central rather than peripheral GLP-1R appear to control alcohol intake (Sirohi et al., 2016), brain regions central for semaglutide’s ability to reduce alcohol intake remains to be determined.”
BackgroundFeduccia, A. A., Simms, J. A., Mill, D., Yi, H. Y., & Bartlett, S. E. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12690 · Cited by 73 · cited 2×
“While previous studies in male rats report that varenicline decreases alcohol drinking (Steensland et al., 2007; Ericson et al., 2009; Hendrickson et al., 2010; Feduccia et al., 2014; Froehlich et al., 2017), this was not confirmed in the present study of male and female rats using a similar dose of varenicline.”
BackgroundResultVallöf, D., Kalafateli, A. L., & Jerlhag, E. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-00923-1 · Cited by 72 · cited 8×
“The four treatment sessions (Monday, Wednesday, Friday, Sunday) were separated by one water drinking session, and each rat was injected with all treatments in a stratified manner (see Figure 1A for timeline).”
BackgroundResultInfluentialSelf-citationSteensland, P., Fredriksson, I., Holst, S., Feltmann, K., Franck, J., Schilström, B., & Carlsson, A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.018 · Cited by 65 · cited 1×
“For instance, varenicline displayed a robust decline in rats that consumed high amounts of alcohol for 12 weeks prior to treatment (Steensland et al., 2012).”
BackgroundCombination of Obesity and High-Fat Feeding Diminishes Sensitivity to GLP-1R Agonist Exendin-4
Duca, F. A., Sakar, Y., & Covasa, M. (2013) · Diabetes · doi:10.2337/db12-1204 · Cited by 64 · cited 1×
“A finding in contrast to other behaviors in which HFD blunts the treatment outcome of GLP-1R agonists (Williams et al., 2011; Duca et al., 2013; Mella et al., 2017; Williams et al., 2018; Al Helaili et al., 2020; Vestlund et al., 2022).”
ResultBupropion for weight reduction
Gadde, K. M., & Xiong, G. L. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.1.17 · Cited by 64 · cited 2×
“Another treatment for smoking is the noradrenaline and dopamine reuptake inhibitor and nAChR antagonist, bupropion (for review see (Gadde and Xiong, 2007; Rigotti et al., 2022).”
BackgroundResultColvin, K. J., Killen, H. S., Kanter, M. J., Halperin, M. C., Engel, L., & Currie, P. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249710 · Cited by 61 · cited 1×
“Among areas of interest is those central for reward such as nucleus accumbens, ventral tegmental area and laterodorsal tegmental area as they participate in the interaction between alcohol and GLP-1 (Shirazi et al., 2013; Abtahi et al., 2018; Vallöf et al., 2019; Colvin et al., 2020; Dixon et al., 2020).”
BackgroundFalk, D. E., Castle, I.-J. P., Ryan, M., Fertig, J., & Litten, R. Z. (2015) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000133 · Cited by 59 · cited 2×
“Moreover, as human studies reveal effects of varenicline in smokers with AUD (McKee et al., Mitchell et al., 2012; Litten et al., 2013; Roberts et al., 2017b; Roberts et al., 2017a; Falk et al., 2015; de Bejczy et al., 2015; Verplaetse et al., 2016), the possibility that varenicline reduces alcohol drinking in nicotin…”
BackgroundGLP-1 action in the mouse bed nucleus of the stria terminalis
Williams, D. L., Lilly, N. A., Edwards, I. J., Yao, P., Richards, J. E., & Trapp, S. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.12.007 · Cited by 54 · cited 1×
“A finding in contrast to other behaviors in which HFD blunts the treatment outcome of GLP-1R agonists (Williams et al., 2011; Duca et al., 2013; Mella et al., 2017; Williams et al., 2018; Al Helaili et al., 2020; Vestlund et al., 2022).”
ResultArcego, D. M., Krolow, R., Lampert, C., Toniazzo, A. P., Garcia, E. D. S., Lazzaretti, C., Costa, G., Scorza, C., & Dalmaz, C. (2020) · Appetite · doi:10.1016/j.appet.2020.104739 · Cited by 53 · cited 1×
“Supportively, HFD alters food intake and food-motivated behaviors (Arcego et al., 2020; Altherr et al., 2021).”
BackgroundAccumbal ghrelin and glucagon-like peptide 1 signaling in alcohol reward in female rats
Abtahi, S., Howell, E., & Currie, P. J. (2018) · NeuroReport · doi:10.1097/wnr.0000000000001071 · Cited by 51 · cited 1×
“Among areas of interest is those central for reward such as nucleus accumbens, ventral tegmental area and laterodorsal tegmental area as they participate in the interaction between alcohol and GLP-1 (Shirazi et al., 2013; Abtahi et al., 2018; Vallöf et al., 2019; Colvin et al., 2020; Dixon et al., 2020).”
BackgroundGhrelin and Glucagon-Like Peptide-1: A Gut-Brain Axis Battle for Food Reward
Decarie-Spain, L., & Kanoski, S. E. (2021) · Nutrients · doi:10.3390/nu13030977 · Cited by 45 · cited 1×
“The findings that GLP-1R agonists reduce homeostatic and hedonic feeding and lowers body weight (for review see (Kanoski, 2021), have led to their approval as antiobesity agents (Wilding et al.”
BackgroundTufvesson‐Alm, M., Shevchouk, O. T., & Jerlhag, E. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1092828 · Cited by 38 · cited 2×
“Alcohol consumption is another aspect regulated by GLP-1, as acute or repeated administration of various GLP-1R agonists decreases alcohol intake, alcohol seeking and relapse in animals (for review see (Tufvesson-Alm et al., 2022).”
BackgroundSelf-citationDixon, T. N., McNally, G. P., & Ong, Z. Y. (2020) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.14437 · Cited by 37 · cited 1×
“Among areas of interest is those central for reward such as nucleus accumbens, ventral tegmental area and laterodorsal tegmental area as they participate in the interaction between alcohol and GLP-1 (Shirazi et al., 2013; Abtahi et al., 2018; Vallöf et al., 2019; Colvin et al., 2020; Dixon et al., 2020).”
BackgroundMartins, F. F., Santos-Reis, T., Marinho, T. D. S., Águila, M. B., & Mandarim‐de‐Lacerda, C. A. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121268 · Cited by 37 · cited 2×
“A finding previously shown in preclinical and clinical studies of obesity (Gabery et al., 2020; Wilding et al., 2021; Martins et al., 2022).”
BackgroundResultAltherr, E. B., Rainwater, A., Kaviani, D., Tang, Q., & Güler, A. D. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113470 · Cited by 36 · cited 1×
“Supportively, HFD alters food intake and food-motivated behaviors (Arcego et al., 2020; Altherr et al., 2021).”
BackgroundGLP-1 receptor agonists: Targeting both hyperglycaemia and disease processes in diabetes
Holst, J. J., & Seino, Y. (2009) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.02.017 · Cited by 32
Kalafateli, A. L., Şatır, T. M., Vallöf, D., Zetterberg, H., & Jerlhag, E. (2020) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2020.101969 · Cited by 31 · cited 5×
“The four treatment sessions (Monday, Wednesday, Friday, Sunday) were separated by one water drinking session, and each rat was injected with all treatments in a stratified manner (see Figure 1A for timeline).”
BackgroundInfluentialSelf-citationIntermittent access to a nutritionally complete high-fat diet attenuates alcohol drinking in rats
Sirohi, S., Cleef, A. V., & Davis, J. F. (2016) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2016.12.009 · Cited by 30
Effects of varenicline on alcohol cue reactivity in heavy drinkers
Roberts, W., Harrison, E. L. R., & McKee, S. A. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4667-9 · Cited by 27
Verplaetse, T. L., Pittman, B. P., Shi, J. M., Tetrault, J. M., Coppola, S., & McKee, S. A. (2016) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000208 · Cited by 25 · cited 2×
“Moreover, as human studies reveal effects of varenicline in smokers with AUD (McKee et al., Mitchell et al., 2012; Litten et al., 2013; Roberts et al., 2017b; Roberts et al., 2017a; Falk et al., 2015; de Bejczy et al., 2015; Verplaetse et al., 2016), the possibility that varenicline reduces alcohol drinking in nicotin…”
BackgroundSex differences in the effect of bupropion and naltrexone combination on alcohol drinking in mice
Zhou, Y., Leri, F., Low, M. J., & Kreek, M. J. (2019) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2019.04.004 · Cited by 23 · cited 18×
“Moreover, as human studies reveal effects of varenicline in smokers with AUD (McKee et al., Mitchell et al., 2012; Litten et al., 2013; Roberts et al., 2017b; Roberts et al., 2017a; Falk et al., 2015; de Bejczy et al., 2015; Verplaetse et al., 2016), the possibility that varenicline reduces alcohol drinking in nicotin…”
BackgroundResultInfluentialSöderpalm, B., Danielsson, K., de Bejczy, A., Adermark, L., & Ericson, M. (2019) · Addiction Biology · doi:10.1111/adb.12807 · Cited by 23 · cited 6×
“Successfully, this approach has been tested for the treatment of AUD, where the combination of varenicline and bupropion prevents relapse to alcohol drinking in rats (Soderpalm et al., 2020).”
BackgroundMethodResultInfluentialBinge-like intake of HFD attenuates alcohol intake in rats
SIROHI, S. K., Cleef, A. V., & Davis, J. F. (2016) · Physiology & Behavior · doi:10.1016/j.physbeh.2016.10.006 · Cited by 22
Navarro, M., Luhn, K. L., Kampov‐Polevoy, A. B., Garbutt, J. C., & Thiele, T. E. (2019) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.13992 · Cited by 22 · cited 15×
“Moreover, as human studies reveal effects of varenicline in smokers with AUD (McKee et al., Mitchell et al., 2012; Litten et al., 2013; Roberts et al., 2017b; Roberts et al., 2017a; Falk et al., 2015; de Bejczy et al., 2015; Verplaetse et al., 2016), the possibility that varenicline reduces alcohol drinking in nicotin…”
BackgroundResultInfluentialMella, R., Schmidt, C. B., Romagnoli, P., Teske, J. A., & Perez‐Leighton, C. (2017) · Obesity · doi:10.1002/oby.21939 · Cited by 19 · cited 1×
“A finding in contrast to other behaviors in which HFD blunts the treatment outcome of GLP-1R agonists (Williams et al., 2011; Duca et al., 2013; Mella et al., 2017; Williams et al., 2018; Al Helaili et al., 2020; Vestlund et al., 2022).”
ResultRoberts, W., Verplaetse, T. L., Moore, K. E., Oberleitner, L., Picciotto, M. R., & McKee, S. A. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117699618 · Cited by 18
Coker, C. R., Aguilar, E. A., Snyder, A. E., Bingaman, S. S., Graziane, N., Browning, K. N., Arnold, A. C., & Silberman, Y. (2020) · Alcohol · doi:10.1016/j.alcohol.2020.03.007 · Cited by 18 · cited 4×
“While previous studies have used different designs to decrease alcohol drinking (Sirohi et al., 2017a; Sirohi et al., 2017b; Villavasso et al., 2019; Coker et al., 2020), another design was used as this design previously has been shown to blunt the ability of another GLP-1R agonist to reduce aggressive behaviors (Vest…”
BackgroundMethodResultInfluentialChronic high fat diet impairs glucagon like peptide-1 sensitivity in vagal afferents
Al Helaili, A., Park, S. J., & Beyak, M. J. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.08.045 · Cited by 17
Vestlund, J., Zhang, Q., Shevchouk, O. T., Hovey, D., Lundström, S., Westberg, L., & Jerlhag, E. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02209-0 · Cited by 15 · cited 3×
“A finding in contrast to other behaviors in which HFD blunts the treatment outcome of GLP-1R agonists (Williams et al., 2011; Duca et al., 2013; Mella et al., 2017; Williams et al., 2018; Al Helaili et al., 2020; Vestlund et al., 2022).”
BackgroundMethodResultSelf-citationFroehlich, J. C., Nicholson, E. R., Dilley, J. E., Filosa, N. J., Rademacher, L. C., & Smith, T. N. (2017) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.13432 · Cited by 12 · cited 4×
“Moreover, varenicline appears to have a robust effect on alcohol intake when rats have been deprived of alcohol (Froehlich et al., 2017; Soderpalm et al., 2020), indicating that the treatment outcome also depends on abstinence exposure.”
BackgroundResultInfluentialCzachowski, C. L., Froehlich, J. C., & DeLory, M. J. (2017) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.13562 · Cited by 11 · cited 1×
“Indeed, as opposed to subcutaneous injections to outbred rats as herein, oral administration of varenicline to alcohol preferring rats reduces alcohol intake (Froehlich et al., 2017; Czachowski et al., 2018).”
BackgroundVillavasso, S., Shaw, C., Skripnikova, E., Shah, K., Davis, J. F., & Sirohi, S. (2019) · Nutrients · doi:10.3390/nu11112731 · Cited by 11 · cited 4×
“While previous studies have used different designs to decrease alcohol drinking (Sirohi et al., 2017a; Sirohi et al., 2017b; Villavasso et al., 2019; Coker et al., 2020), another design was used as this design previously has been shown to blunt the ability of another GLP-1R agonist to reduce aggressive behaviors (Vest…”
BackgroundMethodResultInfluentialGrodin, E. N., Burnette, E. M., Green, R., Lim, A. C., Miotto, K. A., & Ray, L. A. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108825 · Cited by 8 · cited 3×
“Although negative findings that are in contrast to other combinatorial pharmacotherapy that additively reduces alcohol drinking (Zhou et al., 2019; Soderpalm et al., 2020; Grodin et al., 2021), they contribute towards an increased knowledge regarding which combinations could have beneficial effects.”
Background
Cited by
Bruns VI, N., Tressler, E. H., Vendruscolo, L. F., Leggio, L., & Farokhnia, M. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107312 · Cited by 89
De Giorgi, R., Ghenciulescu, A., Dziwisz, O., Taquet, M., Adler, A. I., Koychev, I., Upthegrove, R., Solmi, M., McCutcheon, R., Pillinger, T., et al. (2025) · Nature Mental Health · doi:10.1038/s44220-025-00390-x · Cited by 77
“…and semaglutide in rats and mice found a decrease in alcohol use, which was mediated by mesolimbic dopamine pathways involving the nucleus accumbens, the ventral tegmental area and the ventral hippocampus, the dorso-lateral septum, and the nucleus of the solitary tract 59–61, 63– 69 , 72, Opiates .”
What Is Food Noise? A Conceptual Model of Food Cue Reactivity
Hayashi, D., Edwards, C., Emond, J. A., Gilbert-Diamond, D., Butt, M., Rigby, A., & Masterson, T. D. (2023) · Nutrients · doi:10.3390/nu15224809 · Cited by 80
GLP-1 programs the neurovascular landscape
Chen, B., Yu, X., HORVATH-DIANO, C., Ortuño, M. J., Tschöp, M. H., Jastreboff, A. M., & Schneeberger, M. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.09.003 · Cited by 62
GLP-1 Receptor Agonists: Promising Therapeutic Targets for Alcohol Use Disorder
Jerlhag, E. (2025) · Endocrinology · doi:10.1210/endocr/bqaf028 · Cited by 64
Self-citation
Metadata
- Authors
- Aranäs, C., Blid Sköldheden, S., & Jerlhag, E.
- Affiliations
- University of Gothenburg (SE)
- Corresponding author
- Jerlhag, Elisabet
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2023-08-31
- Volume
- 14
- Pages
- 1180512-1180512
- ISSN
- 1663-9812 (ISSN-L)
- PMC
- PMC10500129
- OpenAlex
- W4386308094
- Cited by
- 20
- References
- 65
- Citations by year
- 2026: 7 · 2025: 7 · 2024: 5 · 2023: 1
- FWCI
- 3.98
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Pharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Vetenskapsrådet (2019-01676)
- Sahlgrenska Universitetssjukhuset (723941)
- Adlerbertska Research Foundation
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- alcoholism, semaglutide, GLP-1 receptor agonists, varenicline, bupropion, combination pharmacotherapy, drug synergy, high-fat diet, alcohol consumption, sex differences, rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.